Lipid biomarkers and long-term risk of cancer in the Women's Health Study

Paulette D. Chandler, Yiqing Song, Jennifer Lin, Shumin Zhang, Howard D. Sesso, Samia Mora, Edward L. Giovannucci, Kathryn E. Rexrode, M. Vinayaga Moorthy, Chunying Li, Paul M. Ridker, I. Min Lee, Joann E. Manson, Julie E. Buring, Lu Wang

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Background: Lipid biomarkers, such as HDL-cholesterol concentra tions, have been shown to have positive, inverse, and null association with total, breast, and colorectal cancer risks. Studies of novel lipi biomarkers, such as apolipoprotein A-I (apo A-I) and apolipoprotein B 100 (apo B-100), and cancer risk have been sparse, to our knowledg Objectives: We evaluated the prospective association of total, breas colorectal, and lung cancers and cancer mortality with circulating lipi biomarkers in 15,602 female health professionals in the Women's Healt Study (aged $45 y, free of cardiovascular disease and cancer, and witho hormone replacement therapy or lipid-lowering medications at baseline Design: Cox regression models estimated HRs of cancer endpoin (19 y median follow-up) across quartiles 1 (reference) to 4 of eac lipid biomarker after adjustment for cancer risk factors. Results: Confirmed cases included 2163 incident cancer cases (86 breast, 198 colorectal, and 190 lung cancers) and 647 cancer death Total cancer risk was significantly lower in the highest quartile of ap A-I (adjusted HR: 0.79; 95% CI: 0.70, 0.90; P-trend = 0.0008) an HDL cholesterol (HR: 0.85; 95% CI: 0.75, 0.97; P-trend = 0.01). Fo site-specific cancers, significant associations included colorectal cance risk with HDL cholesterol (HR: 0.63; 95% CI; 0.41, 0.98; P-trend 0.03), triglycerides (HR: 1.86; 95% CI: 1.17, 2.97; P-trend = 0.02), an apo B-100 (HR: 1.60; 95% CI: 1.03, 2.49; P-trend = 0.006) and lun cancer risk with HDL cholesterol (HR: 0.59; 95% CI: 0.38, 0.93; P trend = 0.01). LDL cholesterol was not significantly associated wit risk of total cancer or any site-specific cancers. In time-depende models that were adjusted for the use of a lipid-lowering medicatio after baseline, these associations remained. Conclusions: Lipids were associated with total, lung, and colorect cancer risks in women. Lifestyle interventions for heart-disease pr vention, which reduce apo B-100 or raise HDL cholesterol, may b associated with reduced cancer risk. The Women's Health Study wa registered at clinicaltrials.gov as NCT00000479.

Original languageEnglish (US)
Pages (from-to)1397-1407
Number of pages11
JournalAmerican Journal of Clinical Nutrition
Volume103
Issue number6
DOIs
StatePublished - Jun 1 2016
Externally publishedYes

Fingerprint

Women's Health
Biomarkers
Lipids
Neoplasms
HDL Cholesterol
Apolipoprotein B-100
Lung Neoplasms
Colorectal Neoplasms
Wit and Humor
Apolipoprotein A-I
Hormone Replacement Therapy
Proportional Hazards Models
LDL Cholesterol
Life Style
Heart Diseases
Triglycerides
Breast
Cardiovascular Diseases

Keywords

  • Cancer
  • Lipids
  • Metabolomics
  • Triglycerides
  • Women

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Nutrition and Dietetics

Cite this

Lipid biomarkers and long-term risk of cancer in the Women's Health Study. / Chandler, Paulette D.; Song, Yiqing; Lin, Jennifer; Zhang, Shumin; Sesso, Howard D.; Mora, Samia; Giovannucci, Edward L.; Rexrode, Kathryn E.; Moorthy, M. Vinayaga; Li, Chunying; Ridker, Paul M.; Lee, I. Min; Manson, Joann E.; Buring, Julie E.; Wang, Lu.

In: American Journal of Clinical Nutrition, Vol. 103, No. 6, 01.06.2016, p. 1397-1407.

Research output: Contribution to journalArticle

Chandler, PD, Song, Y, Lin, J, Zhang, S, Sesso, HD, Mora, S, Giovannucci, EL, Rexrode, KE, Moorthy, MV, Li, C, Ridker, PM, Lee, IM, Manson, JE, Buring, JE & Wang, L 2016, 'Lipid biomarkers and long-term risk of cancer in the Women's Health Study', American Journal of Clinical Nutrition, vol. 103, no. 6, pp. 1397-1407. https://doi.org/10.3945/ajcn.115.124321
Chandler, Paulette D. ; Song, Yiqing ; Lin, Jennifer ; Zhang, Shumin ; Sesso, Howard D. ; Mora, Samia ; Giovannucci, Edward L. ; Rexrode, Kathryn E. ; Moorthy, M. Vinayaga ; Li, Chunying ; Ridker, Paul M. ; Lee, I. Min ; Manson, Joann E. ; Buring, Julie E. ; Wang, Lu. / Lipid biomarkers and long-term risk of cancer in the Women's Health Study. In: American Journal of Clinical Nutrition. 2016 ; Vol. 103, No. 6. pp. 1397-1407.
@article{a87870f5af8a4d18a855ba9645601bb9,
title = "Lipid biomarkers and long-term risk of cancer in the Women's Health Study",
abstract = "Background: Lipid biomarkers, such as HDL-cholesterol concentra tions, have been shown to have positive, inverse, and null association with total, breast, and colorectal cancer risks. Studies of novel lipi biomarkers, such as apolipoprotein A-I (apo A-I) and apolipoprotein B 100 (apo B-100), and cancer risk have been sparse, to our knowledg Objectives: We evaluated the prospective association of total, breas colorectal, and lung cancers and cancer mortality with circulating lipi biomarkers in 15,602 female health professionals in the Women's Healt Study (aged $45 y, free of cardiovascular disease and cancer, and witho hormone replacement therapy or lipid-lowering medications at baseline Design: Cox regression models estimated HRs of cancer endpoin (19 y median follow-up) across quartiles 1 (reference) to 4 of eac lipid biomarker after adjustment for cancer risk factors. Results: Confirmed cases included 2163 incident cancer cases (86 breast, 198 colorectal, and 190 lung cancers) and 647 cancer death Total cancer risk was significantly lower in the highest quartile of ap A-I (adjusted HR: 0.79; 95{\%} CI: 0.70, 0.90; P-trend = 0.0008) an HDL cholesterol (HR: 0.85; 95{\%} CI: 0.75, 0.97; P-trend = 0.01). Fo site-specific cancers, significant associations included colorectal cance risk with HDL cholesterol (HR: 0.63; 95{\%} CI; 0.41, 0.98; P-trend 0.03), triglycerides (HR: 1.86; 95{\%} CI: 1.17, 2.97; P-trend = 0.02), an apo B-100 (HR: 1.60; 95{\%} CI: 1.03, 2.49; P-trend = 0.006) and lun cancer risk with HDL cholesterol (HR: 0.59; 95{\%} CI: 0.38, 0.93; P trend = 0.01). LDL cholesterol was not significantly associated wit risk of total cancer or any site-specific cancers. In time-depende models that were adjusted for the use of a lipid-lowering medicatio after baseline, these associations remained. Conclusions: Lipids were associated with total, lung, and colorect cancer risks in women. Lifestyle interventions for heart-disease pr vention, which reduce apo B-100 or raise HDL cholesterol, may b associated with reduced cancer risk. The Women's Health Study wa registered at clinicaltrials.gov as NCT00000479.",
keywords = "Cancer, Lipids, Metabolomics, Triglycerides, Women",
author = "Chandler, {Paulette D.} and Yiqing Song and Jennifer Lin and Shumin Zhang and Sesso, {Howard D.} and Samia Mora and Giovannucci, {Edward L.} and Rexrode, {Kathryn E.} and Moorthy, {M. Vinayaga} and Chunying Li and Ridker, {Paul M.} and Lee, {I. Min} and Manson, {Joann E.} and Buring, {Julie E.} and Lu Wang",
year = "2016",
month = "6",
day = "1",
doi = "10.3945/ajcn.115.124321",
language = "English (US)",
volume = "103",
pages = "1397--1407",
journal = "American Journal of Clinical Nutrition",
issn = "0002-9165",
publisher = "American Society for Nutrition",
number = "6",

}

TY - JOUR

T1 - Lipid biomarkers and long-term risk of cancer in the Women's Health Study

AU - Chandler, Paulette D.

AU - Song, Yiqing

AU - Lin, Jennifer

AU - Zhang, Shumin

AU - Sesso, Howard D.

AU - Mora, Samia

AU - Giovannucci, Edward L.

AU - Rexrode, Kathryn E.

AU - Moorthy, M. Vinayaga

AU - Li, Chunying

AU - Ridker, Paul M.

AU - Lee, I. Min

AU - Manson, Joann E.

AU - Buring, Julie E.

AU - Wang, Lu

PY - 2016/6/1

Y1 - 2016/6/1

N2 - Background: Lipid biomarkers, such as HDL-cholesterol concentra tions, have been shown to have positive, inverse, and null association with total, breast, and colorectal cancer risks. Studies of novel lipi biomarkers, such as apolipoprotein A-I (apo A-I) and apolipoprotein B 100 (apo B-100), and cancer risk have been sparse, to our knowledg Objectives: We evaluated the prospective association of total, breas colorectal, and lung cancers and cancer mortality with circulating lipi biomarkers in 15,602 female health professionals in the Women's Healt Study (aged $45 y, free of cardiovascular disease and cancer, and witho hormone replacement therapy or lipid-lowering medications at baseline Design: Cox regression models estimated HRs of cancer endpoin (19 y median follow-up) across quartiles 1 (reference) to 4 of eac lipid biomarker after adjustment for cancer risk factors. Results: Confirmed cases included 2163 incident cancer cases (86 breast, 198 colorectal, and 190 lung cancers) and 647 cancer death Total cancer risk was significantly lower in the highest quartile of ap A-I (adjusted HR: 0.79; 95% CI: 0.70, 0.90; P-trend = 0.0008) an HDL cholesterol (HR: 0.85; 95% CI: 0.75, 0.97; P-trend = 0.01). Fo site-specific cancers, significant associations included colorectal cance risk with HDL cholesterol (HR: 0.63; 95% CI; 0.41, 0.98; P-trend 0.03), triglycerides (HR: 1.86; 95% CI: 1.17, 2.97; P-trend = 0.02), an apo B-100 (HR: 1.60; 95% CI: 1.03, 2.49; P-trend = 0.006) and lun cancer risk with HDL cholesterol (HR: 0.59; 95% CI: 0.38, 0.93; P trend = 0.01). LDL cholesterol was not significantly associated wit risk of total cancer or any site-specific cancers. In time-depende models that were adjusted for the use of a lipid-lowering medicatio after baseline, these associations remained. Conclusions: Lipids were associated with total, lung, and colorect cancer risks in women. Lifestyle interventions for heart-disease pr vention, which reduce apo B-100 or raise HDL cholesterol, may b associated with reduced cancer risk. The Women's Health Study wa registered at clinicaltrials.gov as NCT00000479.

AB - Background: Lipid biomarkers, such as HDL-cholesterol concentra tions, have been shown to have positive, inverse, and null association with total, breast, and colorectal cancer risks. Studies of novel lipi biomarkers, such as apolipoprotein A-I (apo A-I) and apolipoprotein B 100 (apo B-100), and cancer risk have been sparse, to our knowledg Objectives: We evaluated the prospective association of total, breas colorectal, and lung cancers and cancer mortality with circulating lipi biomarkers in 15,602 female health professionals in the Women's Healt Study (aged $45 y, free of cardiovascular disease and cancer, and witho hormone replacement therapy or lipid-lowering medications at baseline Design: Cox regression models estimated HRs of cancer endpoin (19 y median follow-up) across quartiles 1 (reference) to 4 of eac lipid biomarker after adjustment for cancer risk factors. Results: Confirmed cases included 2163 incident cancer cases (86 breast, 198 colorectal, and 190 lung cancers) and 647 cancer death Total cancer risk was significantly lower in the highest quartile of ap A-I (adjusted HR: 0.79; 95% CI: 0.70, 0.90; P-trend = 0.0008) an HDL cholesterol (HR: 0.85; 95% CI: 0.75, 0.97; P-trend = 0.01). Fo site-specific cancers, significant associations included colorectal cance risk with HDL cholesterol (HR: 0.63; 95% CI; 0.41, 0.98; P-trend 0.03), triglycerides (HR: 1.86; 95% CI: 1.17, 2.97; P-trend = 0.02), an apo B-100 (HR: 1.60; 95% CI: 1.03, 2.49; P-trend = 0.006) and lun cancer risk with HDL cholesterol (HR: 0.59; 95% CI: 0.38, 0.93; P trend = 0.01). LDL cholesterol was not significantly associated wit risk of total cancer or any site-specific cancers. In time-depende models that were adjusted for the use of a lipid-lowering medicatio after baseline, these associations remained. Conclusions: Lipids were associated with total, lung, and colorect cancer risks in women. Lifestyle interventions for heart-disease pr vention, which reduce apo B-100 or raise HDL cholesterol, may b associated with reduced cancer risk. The Women's Health Study wa registered at clinicaltrials.gov as NCT00000479.

KW - Cancer

KW - Lipids

KW - Metabolomics

KW - Triglycerides

KW - Women

UR - http://www.scopus.com/inward/record.url?scp=84973097248&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84973097248&partnerID=8YFLogxK

U2 - 10.3945/ajcn.115.124321

DO - 10.3945/ajcn.115.124321

M3 - Article

C2 - 27099252

AN - SCOPUS:84973097248

VL - 103

SP - 1397

EP - 1407

JO - American Journal of Clinical Nutrition

JF - American Journal of Clinical Nutrition

SN - 0002-9165

IS - 6

ER -